Across TCGA pan-cancer cohorts, TTC32 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TTC32 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TTC32 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TTC32 expression acts as an unfavorable survival marker.
KIRC and LUAD are the cancer types where TTC32 Mutation most reproducibly stratifies survival.